Roche Holding AG (LTS:0QOK)
CHF 248.4 1.25 (0.51%) Market Cap: 201.45 Bil Enterprise Value: 231.01 Bil PE Ratio: 18.78 PB Ratio: 6.84 GF Score: 84/100

Roche Holding AG Neuroscience Update IR Event Transcript

Oct 30, 2023 / 04:00PM GMT
Release Date Price: CHF239.58 (-0.18%)
Operator

(technical difficulty) (Operator Instructions) One last remark, if you would like to follow the presented slides on as well, please feel free to go to roche.com/investors to download the presentation. At this time, it's my pleasure to introduce you to Bruno Eschli, Head of Investor Relations. Bruno, the stage is yours.

Bruno Eschli
Roche Holding AG - Head of IR

Thanks a lot, [Henrik.] And could I have the first slide, please?

So welcome to our fifth IR call here in 2023 and this time focusing on the Roche Neuroscience franchise. And especially, we want to focus today on the latest data presented during October at recent conferences, ECTRIMS and CTAD. So let me quickly take you through today's agenda.

We have today 3 speakers with us, 2 internal ones and 1 external. The first one is Paulo Fontoura, our Global Head of Neuroscience, Immunology, Ophthalmology, Infectors and Rare Diseases for the Clinical Development. Paulo will provide us an update on the overall Neuroscience franchise strategy. And he also will especially cover the molecules,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot